2 results
Approved WMOPending
To determine the safety and tolerability and to establish a preliminary RP2D and/or an MTD or an MAD of MK-4464 administered via IV infusion as monotherapy and in combination with pembrolizumab IV infusion
Approved WMOCompleted
To investigate the potential influence of time of dosing (morning or evening)on the bronchodilator effect of once daily orally inhaled QVM149 compared toplacebo.